Tracy Marshbanks Insider Trade for 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP); Xilinx (XLNX) Shorts Decreased By 16.77%

Xilinx, Inc. (NASDAQ:XLNX) Logo

Xilinx Inc (NASDAQ:XLNX) had a decrease of 16.77% in short interest. XLNX’s SI was 4.79 million shares in April as released by FINRA. Its down 16.77% from 5.76 million shares previously. With 2.43 million avg volume, 2 days are for Xilinx Inc (NASDAQ:XLNX)’s short sellers to cover XLNX’s short positions. The stock decreased 4.57% or $3.11 during the last trading session, reaching $64.9. About 7.33 million shares traded or 157.54% up from the average. Xilinx, Inc. (NASDAQ:XLNX) has risen 23.85% since April 20, 2017 and is uptrending. It has outperformed by 12.30% the S&P500.

Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. The company has market cap of $16.54 billion. The Company’s programmable devices comprise integrated circuits in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP). It has a 33.75 P/E ratio. The firm also offers development boards; development kits, including hardware, design tools, IP, and reference creates that are designed to streamline and accelerate the development of domain-specific and market-specific applications; and configuration products, such as one-time programmable and in-system programmable storage devices to configure field programmable gate arrays.

Among 25 analysts covering Xilinx Inc. (NASDAQ:XLNX), 8 have Buy rating, 4 Sell and 13 Hold. Therefore 32% are positive. Xilinx Inc. has $87.0 highest and $41 lowest target. $69.96’s average target is 7.80% above currents $64.9 stock price. Xilinx Inc. had 70 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Rosenblatt on Wednesday, July 26 with “Hold”. The rating was maintained by Raymond James on Thursday, July 27 with “Hold”. Barclays Capital maintained the stock with “Equal Weight” rating in Thursday, October 20 report. The stock has “Equal-Weight” rating by Barclays Capital on Thursday, July 27. As per Thursday, July 27, the company rating was maintained by KeyBanc Capital Markets. Wells Fargo maintained the shares of XLNX in report on Thursday, January 25 with “Market Perform” rating. The rating was upgraded by Morgan Stanley to “Overweight” on Thursday, December 15. KeyBanc Capital Markets maintained the shares of XLNX in report on Wednesday, September 6 with “Buy” rating. Wells Fargo downgraded the stock to “Market Perform” rating in Tuesday, May 23 report. Deutsche Bank maintained Xilinx, Inc. (NASDAQ:XLNX) on Thursday, October 26 with “Hold” rating.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.33, from 0.88 in 2017Q3. It is positive, as 43 investors sold Xilinx, Inc. shares while 169 reduced holdings. 76 funds opened positions while 181 raised stakes. 221.90 million shares or 4.44% less from 232.20 million shares in 2017Q3 were reported. Northwestern Mutual Wealth Management Co invested 0% in Xilinx, Inc. (NASDAQ:XLNX). Citadel Advisors Limited Liability Com accumulated 580,871 shares. Fort Washington Inv Advsrs Oh invested in 0.03% or 47,566 shares. Dnb Asset Mngmt As holds 26,166 shares or 0.02% of its portfolio. Bb&T has invested 0.03% in Xilinx, Inc. (NASDAQ:XLNX). Jensen accumulated 8,840 shares or 0.01% of the stock. Rosenbaum Jay D accumulated 12,545 shares or 1.56% of the stock. Shine Invest Advisory invested 0.07% in Xilinx, Inc. (NASDAQ:XLNX). Brown Advisory Incorporated has invested 0% of its portfolio in Xilinx, Inc. (NASDAQ:XLNX). New Jersey-based Systematic Limited Partnership has invested 0.08% in Xilinx, Inc. (NASDAQ:XLNX). Atlantic Tru Group Limited Liability holds 0.03% or 98,149 shares. Moneta Gp Advisors Limited Liability Co reported 0% in Xilinx, Inc. (NASDAQ:XLNX). Trillium Asset Ltd owns 129,987 shares. California-based Parallax Volatility Advisers L P has invested 0% in Xilinx, Inc. (NASDAQ:XLNX). Balyasny Asset Management Limited Liability Corporation has invested 0.05% in Xilinx, Inc. (NASDAQ:XLNX).

Since October 30, 2017, it had 0 insider purchases, and 4 insider sales for $5.48 million activity. Tong Vincent sold $1.45M worth of Xilinx, Inc. (NASDAQ:XLNX) on Thursday, February 1. 20,000 shares were sold by GAVRIELOV MOSHE, worth $1.52 million. The insider Hover-Smoot Scott sold 4,300 shares worth $308,396.

The stock decreased 1.61% or $0.99 during the last trading session, reaching $60.64. About 100,085 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 18.93% since April 20, 2017 and is uptrending. It has outperformed by 7.38% the S&P500.

Investors sentiment decreased to 1.09 in Q4 2017. Its down 0.60, from 1.69 in 2017Q3. It worsened, as 13 investors sold ANI Pharmaceuticals, Inc. shares while 43 reduced holdings. 23 funds opened positions while 38 raised stakes. 6.25 million shares or 0.89% less from 6.31 million shares in 2017Q3 were reported. Caprock Gp Inc has invested 0.06% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). New York-based Jpmorgan Chase & has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Piermont has invested 0.13% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). California Pub Employees Retirement Systems holds 0% or 17,700 shares in its portfolio. Parametric Portfolio Associates Ltd Com accumulated 0% or 15,360 shares. Wisconsin-based State Of Wisconsin Invest Board has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). New York State Common Retirement Fund, a New York-based fund reported 11,630 shares. Mason Street Advisors Ltd holds 0% or 2,331 shares in its portfolio. Ls Invest Advisors Limited Liability Corp holds 0.01% or 1,704 shares. Citigroup reported 25,877 shares. Prudential Inc invested in 0% or 15,050 shares. Raymond James & Associate owns 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 21,462 shares. Sei Investments holds 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 1,435 shares. Kbc Grp Nv owns 0.01% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 16,057 shares. Tci Wealth reported 15 shares or 0% of all its holdings.

Analysts await ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report earnings on May, 3. They expect $1.10 earnings per share, up 77.42% or $0.48 from last year’s $0.62 per share. ANIP’s profit will be $12.90M for 13.78 P/E if the $1.10 EPS becomes a reality. After $1.00 actual earnings per share reported by ANI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.00% EPS growth.

A legal report filed with the Washington-based Security and Exchange Commission on 19/04/2018 shared that Tracy Marshbanks, the director of Ani Pharmaceuticals Inc, ‘s company unloaded 33,200 shares. With average price per share of $62.1 the significant transaction’s amount is $2,061,388 U.S. Dollars. Right now, she has in hand a total of 450,601 shares or 3.84% of Ani Pharmaceuticals Inc’s market capitalization (total value of the shares outstanding).

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma has $82 highest and $50 lowest target. $66.20’s average target is 9.17% above currents $60.64 stock price. ANI Pharma had 20 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by TH Capital with “Neutral” on Tuesday, August 4. Canaccord Genuity maintained it with “Buy” rating and $6000 target in Wednesday, August 9 report. As per Tuesday, July 19, the company rating was upgraded by Oppenheimer. As per Thursday, June 23, the company rating was initiated by Raymond James. On Wednesday, February 22 the stock rating was downgraded by TH Capital to “Neutral”. The company was downgraded on Wednesday, September 2 by TheStreet. On Wednesday, February 28 the stock rating was maintained by Canaccord Genuity with “Buy”. Roth Capital upgraded ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) rating on Monday, September 28. Roth Capital has “Buy” rating and $60 target. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has “Hold” rating given on Thursday, November 2 by Roth Capital. Canaccord Genuity maintained the shares of ANIP in report on Monday, October 16 with “Buy” rating.

Since March 1, 2018, it had 0 insider purchases, and 7 sales for $9.84 million activity. Another trade for 1,912 shares valued at $120,647 was made by MARSHBANKS TRACY on Wednesday, March 14. RAYNOR DANIEL had sold 27,964 shares worth $1.74M on Monday, March 12. Marken James G. had sold 4,177 shares worth $258,640. Schrepfer Robert W sold $1.77M worth of stock or 28,652 shares. Shares for $1.47 million were sold by PRZYBYL ARTHUR.

Xilinx, Inc. (NASDAQ:XLNX) Institutional Positions Chart